TABLE 4.
Treatment-emergent adverse events occurring in >1 patient in either substudy during monotherapy treatment period
| Adverse event | No. (%)a |
|
|---|---|---|
| Substudy 1 (ABT-493) (n = 49) | Substudy 2 (ABT-530) (n = 40) | |
| Headache | 11 (22.4) | 4 (10.0) |
| Diarrhea | 3 (6.1) | 1 (2.5) |
| Abdominal discomfort | 3 (6.1) | 0 |
| Fatigue | 3 (6.1) | 0 |
| Rash | 3 (6.1) | 0 |
| Dizziness | 2 (4.1) | 0 |
| Myalgia | 2 (4.1) | 0 |
| Nausea | 2 (4.1) | 2 (5.0) |
| Pruritus | 2 (4.1) | 0 |
| Constipation | 0 | 2 (5.0) |
a
Number of treatment-emergent adverse events that occurred in patients from any dose group in either substudy.